Announcements Trials
Browse Landscape

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 9Observational 4

Sponsor

Cancer Type

Thoracic 3CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Neuroblastoma 1ALK-positive NSCLC 1

Interventions

Sunitinib 16exemestane 11Afatinib 11palbociclib 10Rituximab 10Bevacizumab 10Erlotinib Hydrochloride 9Leuprolide 8Radiotherapy 7Drug Therapy 7Axitinib 7avelumab 6Letrozole 6Capecitabine 6Blood Specimen Collection 6enzalutamide 5Trastuzumab 5Surveys and Questionnaires 5Standard of Care 5Docetaxel 5Aromatase Inhibitors 5lorlatinib 4Specimen Handling 4Radiation 4Mammography 4Crizotinib 4Anastrozole 4Abiraterone Acetate 4temsirolimus 3talazoparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × Has results × lorlatinib × Clear all
NCT06282991 2026-03-10

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Pfizer

Completed
73 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

Pfizer

Completed
5,279 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04753658 2024-09-23

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

Pfizer

Terminated
15 enrolled 22 charts
CNS

Neuroblastoma

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

Completed
549 enrolled 28 charts
Thoracic

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡